Loading
Latest filing published 03 Jun 2022 for INVO Bioscience, Inc., €9,386.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
All filings by Michael Jos. Campbell on record concern INVO Fertility, Inc., in the capacity of chief executive. Over a trading history stretching from 22 January 2018 to 1 June 2022, the count stands at 5 filings.
No open-market sale appears; the market trades are 1 purchase worth €9,386. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 4 share grants. Since January 2022: 1 purchase and no sales on the market.
The latest filing, published on 3 June 2022, reports an open-market purchase of €9,386 in INVO Fertility, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations